Tranexamic acid
- Generic Name
- Tranexamic acid
- Brand Names
- Cyklokapron, Lysteda
- Drug Type
- Small Molecule
- Chemical Formula
- C8H15NO2
- CAS Number
- 1197-18-8
- Unique Ingredient Identifier
- 6T84R30KC1
- Background
Tranexamic acid is a synthetic derivative of lysine used as an antifibrinolytic in the treatment and prevention of major bleeding. It possesses a similar mechanism of action to aminocaproic acid but is approximately 10-fold more potent.
It was first patented in 1957 and received its initial US approval in 1986.
- Indication
Taken orally, tranexamic acid is indicated for the treatment of hereditary angioedema, cyclic heavy menstrual bleeding in premenopausal females, and other instances of significant bleeding in the context of hyperfibrinolysis. Given intravenously, tranexamic acid is indicated for short-term use (2-8 days) in patients with hemophilia to prevent or reduce bleed...
- Associated Conditions
- Bleeding, Heavy Menstrual Bleeding, Hereditary Angioedema (HAE)
- Associated Therapies
- -
Tranexamic Acid, Hemorrhage and Transfusions After Combined Aortic Valve Replacement and Coronary Artery Bypass Surgery.
- First Posted Date
- 2006-09-13
- Last Posted Date
- 2012-12-13
- Lead Sponsor
- St. Olavs Hospital
- Target Recruit Count
- 63
- Registration Number
- NCT00375466
- Locations
- 🇳🇴
St. Olav University Hospital, Trondheim, Norway
Tranexamic Acid Study
- Conditions
- First Posted Date
- 2006-09-13
- Last Posted Date
- 2015-10-05
- Lead Sponsor
- Texas Tech University Health Sciences Center
- Registration Number
- NCT00375440
- Locations
- 🇺🇸
Texas Tech University Health Sciences Center Department of Orthopaedic Surgery, Lubbock, Texas, United States
Clinical Randomisation of an Antifibrinolytic in Significant Haemorrhage
- First Posted Date
- 2006-09-12
- Last Posted Date
- 2011-06-30
- Lead Sponsor
- London School of Hygiene and Tropical Medicine
- Target Recruit Count
- 20211
- Registration Number
- NCT00375258
- Locations
- 🇬🇧
Over 50 countries Worldwide, London, United Kingdom
ATERO : A Randomised Study With Tranexamic Acid in Epistaxis of Rendu Osler Syndrome
- Conditions
- First Posted Date
- 2006-07-21
- Last Posted Date
- 2019-05-28
- Lead Sponsor
- Hospices Civils de Lyon
- Target Recruit Count
- 170
- Registration Number
- NCT00355108
- Locations
- 🇫🇷
Henri PLAUCHU, Lyon, France
Tranexamic Acid and Head and Neck Surgery Patients
- Conditions
- First Posted Date
- 2006-03-30
- Last Posted Date
- 2006-03-30
- Lead Sponsor
- Taichung Veterans General Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT00308880
- Locations
- 🇨🇳
Taichung Veterans General Hospital, Taichung, Taiwan
Does Tranexamic Acid Administration Reduce Blood Loss During Head and Neck Surgery?
- Conditions
- First Posted Date
- 2005-09-07
- Last Posted Date
- 2007-02-07
- Lead Sponsor
- Tata Memorial Hospital
- Target Recruit Count
- 240
- Registration Number
- NCT00147862
- Locations
- 🇮🇳
Tata Memorial Hospital, Mumbai, Maharashtra, India
Treatment and Management of Women With Bleeding Disorders
- Conditions
- First Posted Date
- 2005-05-19
- Last Posted Date
- 2007-03-13
- Lead Sponsor
- Centers for Disease Control and Prevention
- Target Recruit Count
- 100
- Registration Number
- NCT00111215
- Locations
- 🇺🇸
The Mayo Clinic, Rochester, Minnesota, United States
🇺🇸UMDNJ Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States
🇺🇸Michigan State University, East Lansing, Michigan, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.